本文已被:浏览 1855次 下载 591次 |
码上扫一扫! |
|
程序性死亡因子-1抑制剂在血液系统恶性肿瘤治疗中的研究进展 |
王春晖1, 李倩雯1,2, 李晓宇1, 吕迁洲1, 刘澎3
|
1.复旦大学附属中山医院药剂科, 上海 200032;2.复旦大学药学院, 上海 200433;3.复旦大学附属中山医院血液科, 上海 200032
|
|
摘要: |
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的应用是一种新型免疫治疗手段。阻断程序性死亡因子-1(programmed death 1,PD-1)与其配体(PD-L1)结合,可避免免疫逃逸,恢复机体免疫应答,发挥其抗肿瘤效应,是目前抗肿瘤治疗中炙手可热的方法之一。PD-1抑制剂在越来越多的实体瘤治疗中表现出较好疗效,但在血液系统恶性肿瘤中的应用仍相对有限。本文回顾PD-1抑制剂在血液系统恶性肿瘤中的临床研究,探讨其临床应用前景。 |
关键词: 免疫检查点抑制剂 程序性死亡因子-1 霍奇金淋巴瘤 非霍奇金淋巴瘤 弥漫性大B细胞淋巴瘤 NK/T细胞淋巴瘤 多发性骨髓瘤 |
DOI:10.12025/j.issn.1008-6358.2021.20202004 |
分类号:R979.5 |
基金项目:上海市卫生计生系统重要薄弱学科建设项目(2016ZB0301),上海市临床重点专科(临床药学)项目(shslczdzk06504). |
|
Research progress of programmed death-1 inhibitor in treatment of hematologic malignancies |
WANG Chun-hui1, LI Qian-wen1,2, LI Xiao-Yu1, LV Qian-zhou1, LIU Peng3
|
1.Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China;2.School of Pharmacy, Fudan University, Shanghai 200433, China;3.Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
|
Abstract: |
Immune checkpoint inhibitors (ICIs), as a new immunotherapy strategy, avoid immune escape and restore the human body's immune response by blocking the binding of programmed death-1 (PD-1) and its ligand PD-L1 to enhance the anti-tumor effect of the body's immune system. ICIs have become one of the most popular fields of anti-tumor therapy. PD-1 inhibitors have shown good efficacy in the treatment of more and more solid tumors. However, the application experience in hematological malignancies is still relatively limited. This article reviews the clinical studies on PD-1 inhibitors in hematologic malignancies and discusses its clinical application prospect. |
Key words: immune checkpoint inhibitors programmed death 1 Hodgkin lymphoma non-Hodgkin lymphoma diffuse large B-cell lymphoma NK/T cell lymphoma multiple myeloma |